NEWS

This news item provides a copy of a press release from RedHill BioPharma that gives more details about their clinical trial findings. Key findings:

Primary endpoint successfully achieved - superior remission rate at week 26 in patients treated with RHB-104 (p= 0.013).

Key secondary endpoints also met, demonstrating consistent benefit to Crohn’s disease patients treated with RHB-104.

Comment: The real proof is in the final peer reviewed publication: Repeating comments from the prior new item, if the final published results of this trial are consistent with the claims in this press release, it represents a final piece of evidence indicating that MAP is a cause of Crohn’s disease. This would heighten the need for veterinary medicine, animal agriculture, and relevant governmental agencies concerned with food safety to limit contamination of food and water by MAP.

Press Release

Welcome to the updated and improved johnes.org!! 

Thanks to the support from our generous sponsors, our website has a fresh look, more images, and 100% edited and updated content. We give special thanks to our platinum sponsors, Zoetis and encourage you to follow links to their home pages.

If you are on our e-list, you will continue to receive notification of updates and news items. If you wish your name to be added to our e-list, click the "subscribe" button in the footer.